Fiducient Advisors LLC increased its position in Colgate-Palmolive (NYSE:CL – Free Report) by 5.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,231 shares of the company’s stock after acquiring an additional 110 shares during the period. Fiducient Advisors LLC’s holdings in Colgate-Palmolive were worth $232,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of CL. Diversify Advisory Services LLC acquired a new position in shares of Colgate-Palmolive during the first quarter worth approximately $911,000. TD Asset Management Inc grew its stake in shares of Colgate-Palmolive by 2.4% in the first quarter. TD Asset Management Inc now owns 1,154,566 shares of the company’s stock worth $103,969,000 after purchasing an additional 26,987 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of Colgate-Palmolive by 277.3% during the first quarter. Empowered Funds LLC now owns 33,082 shares of the company’s stock valued at $2,979,000 after purchasing an additional 24,314 shares during the period. M&G Plc bought a new stake in shares of Colgate-Palmolive during the first quarter valued at about $3,812,000. Finally, Sei Investments Co. lifted its holdings in Colgate-Palmolive by 41.5% in the first quarter. Sei Investments Co. now owns 598,639 shares of the company’s stock worth $53,901,000 after purchasing an additional 175,445 shares during the period. 80.41% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
CL has been the topic of several research analyst reports. Jefferies Financial Group cut shares of Colgate-Palmolive from a “buy” rating to a “hold” rating and lowered their target price for the company from $103.00 to $95.00 in a research note on Wednesday, July 24th. Citigroup boosted their target price on Colgate-Palmolive from $103.00 to $112.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Bank of America increased their price target on Colgate-Palmolive from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. TD Cowen dropped their price objective on Colgate-Palmolive from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Piper Sandler assumed coverage on Colgate-Palmolive in a research note on Tuesday, September 24th. They set an “overweight” rating and a $121.00 target price for the company. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $105.11.
Colgate-Palmolive Stock Performance
Shares of Colgate-Palmolive stock opened at $94.69 on Thursday. Colgate-Palmolive has a 12 month low of $73.97 and a 12 month high of $109.30. The company has a quick ratio of 0.70, a current ratio of 1.06 and a debt-to-equity ratio of 16.90. The stock has a market cap of $77.69 billion, a PE ratio of 29.97, a price-to-earnings-growth ratio of 3.54 and a beta of 0.40. The business has a fifty day simple moving average of $102.69 and a 200-day simple moving average of $98.17.
Colgate-Palmolive Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Friday, October 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 18th. This represents a $2.00 dividend on an annualized basis and a yield of 2.11%. Colgate-Palmolive’s payout ratio is presently 63.29%.
Insider Activity
In related news, insider Panagiotis Tsourapas sold 14,794 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $102.94, for a total transaction of $1,522,894.36. Following the transaction, the insider now directly owns 5,146 shares of the company’s stock, valued at approximately $529,729.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Colgate-Palmolive news, insider Panagiotis Tsourapas sold 14,794 shares of the company’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $102.94, for a total value of $1,522,894.36. Following the transaction, the insider now directly owns 5,146 shares of the company’s stock, valued at $529,729.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sally Massey sold 15,850 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total value of $1,636,988.00. Following the sale, the insider now directly owns 13,942 shares of the company’s stock, valued at $1,439,929.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 43,490 shares of company stock worth $4,486,063 in the last 90 days. Company insiders own 0.34% of the company’s stock.
About Colgate-Palmolive
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
Further Reading
- Five stocks we like better than Colgate-Palmolive
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Top Bill Gates Stock Picks Every Investor Should Know About
- How to Invest in the Best Canadian StocksÂ
- Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
- How Can Investors Benefit From After-Hours Trading
- Boeing: Why Analysts Think Now’s The Time To Be Brave
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL – Free Report).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.